---
title: "Supporting Confident Manufacturing Changes: How Kerry (formerly c-LEcta) helps You Navigate FDAs New Regulatory Flexibility"
description: Whether you are considerung the replacement of a trypsin-like enzyme or an endonuclease in approved manufacturing processes, our documents will support you
---

[Denarase® News | Kerry (formerly c-LEcta) ](https://denarase.c-lecta.com/denarase-news)

# [Supporting Confident Manufacturing Changes: How Kerry (formerly c-LEcta) helps You Navigate FDAs New Regulatory Flexibility](https://denarase.c-lecta.com/denarase-news/supporting-confident-manufacturing-changes)

 Written by [c-LEcta](https://denarase.c-lecta.com/denarase-news/author/c-lecta) | Mar 31, 2026 8:37:55 AM

In January 2026, the U.S. FDA publicly reinforced a **flexible, risk-based approach** to CMC requirements for cell and gene therapies. The agency emphasized that **minor manufacturing changes can be supported by focused, science-driven comparability data** rather than disproportionate revalidation efforts: **[See here!](https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/flexible-requirements-cell-and-gene-therapies-advance-innovation)**

This regulatory approach strongly aligns with  Kerry's (formerly c-LEcta) Change Guidance Documents, which help manufacturers manage raw and ancillary material changes in approved biopharmaceutical manufacturing processes.

Kerry provides customers with clear, regulatory-aligned support for an efficient and confident implementation of changes covering

- Defined qualification elements
- Structured Risk assessments
- Targeted Comparability activities.

Together, FDA’s clarified flexibility and Kerry's practical change guidance underscore a shared principle: manufacturing change is a normal, expected part of a product’s lifecycle - and, with the right scientific framework and regulatory support, it can be executed efficiently, safely and without unnecessary delay.

Whether you are considerung the replacement of a trypsin-like enzyme or an endonuclease in your approved manufacturing process - Kerry's **Change Guidance** **Documents** help you navigate raw and ancillary material changes with confidence, using a regulatory aligned framework.

[View full post](https://denarase.c-lecta.com/denarase-news/supporting-confident-manufacturing-changes)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "c-LEcta"
  },
  "dateModified" : "2026-06-10T09:37:53.822Z",
  "datePublished" : "2026-03-31T08:37:55Z",
  "headline" : "Supporting Confident Manufacturing Changes: How Kerry (formerly c-LEcta) helps You Navigate FDAs New Regulatory Flexibility",
  "image" : {
    "@type" : "ImageObject",
    "height" : 60,
    "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
    "width" : 60
  },
  "mainEntityOfPage" : "https://denarase.c-lecta.com/denarase-news/supporting-confident-manufacturing-changes",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "Denarase® News"
  }
}
```